News | October 27, 2025
Sanofi's Q3 profit dips marginally as Dupixent sales top €4 billion
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025
India currently hosts more than 10,075 biotech startups
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Advent acquired Zentiva from Sanofi in 2018 and transformed the company into a highly successful standalone business
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
Subscribe To Our Newsletter & Stay Updated
